Skip to main content Skip to search Skip to main navigation

MDR: Proposal for a delay due to Covid-19

The deadline of 26 May 2020 should have been the date: The European Commission's Medical Device Regulation (MDR) was supposed to come into force. Due to the Corona crisis, the European Commission is now submitting a proposal to postpone the implementation deadline.

Other organisations had already called for this step:

Medical device manufacturers have repeatedly questioned whether the deadline can be met, as there is still a lack of Notified Bodies. The introduction of laws to ensure compliance with the new product standards was also critical in terms of timing (we reported).

In a press release of 23 March 2020, MedTech Europe called for a postponement of the introduction date for MDR and IVDR. Their proposal: Six months after the crisis has been overcome, the implementation should be resumed.

In a letter of 24 March 2020, six Members of the European Parliament address the lack of resources caused by the current crisis in the following areas:

  • Approval of clinical trials
  • Notification and auditing of Notified Bodies
  • Manufacturing

The Members of Parliament are calling to maintain the current system for regulating medical devices. Health systems across Europe need all their resources to deal with the corona crisis.

The proposal for postponement should be submitted in early April and implemented as soon as possible. This information is according to a Q&A session at the European Commission press conference of 25 March 2020.


Sources:

MedTech Europe: Press release

European Commission: Letter of the European Parliament

European Commission: Q&A Press conference Covid-19 and MDR

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next